IMU Biosciences and Waters partner on AI immune profiling platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
June 24, 2026 8:00 AM EDTIMUs AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time.Waters Biosciences technologies, including BD FACSDiscover and BD Rhapsody Instruments, will be used with IMUs AI analytics in research to deliver deeper, population-level disease insights.Partnership supports IMUs expansion of its world-leading immune dataset through large-scale studies, establishing a new standard for immune profiling.
LONDON--(BUSINESS WIRE)-- IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand,... More
